Ambra1 modulates the tumor immune microenvironment and response to PD-1 blockade in melanoma.

in Journal for immunotherapy of cancer (2023), 11(3),

BACKGROUND: Loss of Ambra1 (autophagy and beclin 1 regulator 1), a multifunctional scaffold protein, promotes the formation of nevi and contributes to several phases of melanoma development. The ... [more ▼]

BACKGROUND: Loss of Ambra1 (autophagy and beclin 1 regulator 1), a multifunctional scaffold protein, promotes the formation of nevi and contributes to several phases of melanoma development. The suppressive functions of Ambra1 in melanoma are mediated by negative regulation of cell proliferation and invasion; however, evidence suggests that loss of Ambra1 may also affect the melanoma microenvironment. Here, we investigate the possible impact of Ambra1 on antitumor immunity and response to immunotherapy. METHODS: This study was performed using an Ambra1-depleted Braf(V600E) /Pten(-/) (-) genetically engineered mouse (GEM) model of melanoma, as well as GEM-derived allografts of Braf(V600E) /Pten(-/) (-) and Braf(V600E) /Pten(-/) (-)/Cdkn2a(-/) (-) tumors with Ambra1 knockdown. The effects of Ambra1 loss on the tumor immune microenvironment (TIME) were analyzed using NanoString technology, multiplex immunohistochemistry, and flow cytometry. Transcriptome and CIBERSORT digital cytometry analyses of murine melanoma samples and human melanoma patients (The Cancer Genome Atlas) were applied to determine the immune cell populations in null or low-expressing AMBRA1 melanoma. The contribution of Ambra1 on T-cell migration was evaluated using a cytokine array and flow cytometry. Tumor growth kinetics and overall survival analysis in Braf(V600E) /Pten(-/) (-)/Cdkn2a(-/) (-) mice with Ambra1 knockdown were evaluated prior to and after administration of a programmed cell death protein-1 (PD-1) inhibitor. RESULTS: Loss of Ambra1 was associated with altered expression of a wide range of cytokines and chemokines as well as decreased infiltration of tumors by regulatory T cells, a subpopulation of T cells with potent immune-suppressive properties. These changes in TIME composition were associated with the autophagic function of Ambra1. In the Braf(V600E) /Pten(-/) (-)/Cdkn2a(-/) (-) model inherently resistant to immune checkpoint blockade, knockdown of Ambra1 led to accelerated tumor growth and reduced overall survival, but at the same time conferred sensitivity to anti-PD-1 treatment. CONCLUSIONS: This study shows that loss of Ambra1 affects the TIME and the antitumor immune response in melanoma, highlighting new functions of Ambra1 in the regulation of melanoma biology. [less ▲]

Improving Machine Learning-based Prediction of Frailty in Elderly People with Digital Wearables : Data from the Berlin Aging Study II (BASE-II)

Poster (2022, October 26)

Frailty is a geriatric medical condition that is highly associated with age and age-related diseases. The multidimensional consequences of frailty are heavily impacting the quality of life, and will ... [more ▼]

Frailty is a geriatric medical condition that is highly associated with age and age-related diseases. The multidimensional consequences of frailty are heavily impacting the quality of life, and will inevitably increase the burden on healthcare systems in the future. Most importantly, the lack of a universal standard to describe, diagnose, or let alone treat frailty, is further complicating the situation in the long-term. Nowadays, more and more frailty assessment tools are being developed on a regional and institutional basis, which is continuing to drive the heterogeneity in the characterization of frailty further apart. Gaining better insights into the underlying causes and pathophysiology of frailty, and how it is developing in patients is, therefore, required to establish strong and accurately tailored response schemes for frail patients, where currently only symptoms are treated. Thus, in this study, we deployed machine learning-based classification and optimization techniques to predict frailty in elderly people aged 65 or above from the Berlin Aging Study II (BASE-II, n=1512, frail=484) and revealed some of the most informative biomedical information to characterize frailty, including new potential biomarkers. Frailty in BASE-II was measured by the Fried et al. 5-item frailty index, composed of the clinical variables grip strength, weight loss, exhaustion, physical activity, and gait. The level of frailty in BASE-II was adapted for binary classification purposes by merging the pre-frail and frail levels as frail. A configurable in-house pipeline was developed for pre-processing the clinical data and predicting the target disease by deploying Support Vector Machines Classification. The most informative and essential subgroup of clinical measurements with regards to frailty was investigated by re-optimizing an initially full data-driven model by sequentially leaving out one subgroup. The best prediction power was yielded with resampling and dimensionality reduction techniques using the F-beta-2 score, and was further improved by adding one item of the Fried et al. frailty index. Furthermore, differences between the gender in the data set led to the investigation of gender-specific model configurations, followed by re-optimizations. As a result, we were able to specifically increase the predictive power in gender-specific groups, and will simultaneously emphasize on the differences between the most informative clinical biomarkers as well as the most essential subgroups for mixed and gender-specific BASE-II. The results herein suggest that a combination of the detected easy-to-obtain biomedical information on frailty risk factors together with one Fried et al. phenotype information provided by i.e., smart wearable devices (gait, grip strength, …) could significantly improve the frailty prediction power in mixed and gender-specific clinical cohort data. [less ▲]

Integration of external biomass reactions into existing metabolic models

E-print/Working paper (2022)

Currently, seven biomass objective functions have been defined in human metabolic reconstructions. The integration of published biomass reactions into alternative models can contribute to the prediction ... [more ▼]

Currently, seven biomass objective functions have been defined in human metabolic reconstructions. The integration of published biomass reactions into alternative models can contribute to the prediction power of the model. Thus, in this work, we present a workflow to integrate reactions and biomass functions originating from several genome-scale reconstructions into models other than their home models. Additionally, a benchmark to identify the biomass that confers the highest prediction accuracy in terms of gene essentiality and growth predictions is provided. [less ▲]

Review of Current Human Genome-Scale Metabolic Models for Brain Cancer and Neurodegenerative Diseases.

in Cells (2022), 11(16),

Brain disorders represent 32% of the global disease burden, with 169 million Europeans affected. Constraint-based metabolic modelling and other approaches have been applied to predict new treatments for ... [more ▼]

Brain disorders represent 32% of the global disease burden, with 169 million Europeans affected. Constraint-based metabolic modelling and other approaches have been applied to predict new treatments for these and other diseases. Many recent studies focused on enhancing, among others, drug predictions by generating generic metabolic models of brain cells and on the contextualisation of the genome-scale metabolic models with expression data. Experimental flux rates were primarily used to constrain or validate the model inputs. Bi-cellular models were reconstructed to study the interaction between different cell types. This review highlights the evolution of genome-scale models for neurodegenerative diseases and glioma. We discuss the advantages and drawbacks of each approach and propose improvements, such as building bi-cellular models, tailoring the biomass formulations for glioma and refinement of the cerebrospinal fluid composition. [less ▲]

Bruceine D Identified as a Drug Candidate against Breast Cancer by a Novel Drug Selection Pipeline and Cell Viability Assay.

in Pharmaceuticals (Basel, Switzerland) (2022), 15(2),

The multi-target effects of natural products allow us to fight complex diseases like cancer on multiple fronts. Unlike docking techniques, network-based approaches such as genome-scale metabolic modelling ... [more ▼]

The multi-target effects of natural products allow us to fight complex diseases like cancer on multiple fronts. Unlike docking techniques, network-based approaches such as genome-scale metabolic modelling can capture multi-target effects. However, the incompleteness of natural product target information reduces the prediction accuracy of in silico gene knockout strategies. Here, we present a drug selection workflow based on context-specific genome-scale metabolic models, built from the expression data of cancer cells treated with natural products, to predict cell viability. The workflow comprises four steps: first, in silico single-drug and drug combination predictions; second, the assessment of the effects of natural products on cancer metabolism via the computation of a dissimilarity score between the treated and control models; third, the identification of natural products with similar effects to the approved drugs; and fourth, the identification of drugs with the predicted effects in pathways of interest, such as the androgen and estrogen pathway. Out of the initial 101 natural products, nine candidates were tested in a 2D cell viability assay. Bruceine D, emodin, and scutellarein showed a dose-dependent inhibition of MCF-7 and Hs 578T cell proliferation with IC(50) values between 0.7 to 65 μM, depending on the drug and cell line. Bruceine D, extracted from Brucea javanica seeds, showed the highest potency. [less ▲]

DCcov: Repositioning of drugs and drug combinations for SARS-CoV-2 infected lung through constraint-based modeling.

in iScience (2021), 24(11), 103331

The 2019 coronavirus disease (COVID-19) became a worldwide pandemic with currently no approved effective antiviral drug. Flux balance analysis (FBA) is an efficient method to analyze metabolic networks ... [more ▼]

The 2019 coronavirus disease (COVID-19) became a worldwide pandemic with currently no approved effective antiviral drug. Flux balance analysis (FBA) is an efficient method to analyze metabolic networks. Here, FBA was applied on human lung cells infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to reposition metabolic drugs and drug combinations against the virus replication within the host tissue. Making use of expression datasets of infected lung tissue, genome-scale COVID-19-specific metabolic models were reconstructed. Then, host-specific essential genes and gene pairs were determined through in silico knockouts that permit reducing the viral biomass production without affecting the host biomass. Key pathways that are associated with COVID-19 severity in lung tissue are related to oxidative stress, ferroptosis, and pyrimidine metabolism. By in silico screening of Food and Drug Administration (FDA)-approved drugs on the putative disease-specific essential genes and gene pairs, 85 drugs and 52 drug combinations were predicted as promising candidates for COVID-19 (https://github.com/sysbiolux/DCcov). [less ▲]

Loss of Ambra1 promotes melanoma growth and invasion.

in Nature communications (2021), 12(1), 2550

Melanoma is the deadliest skin cancer. Despite improvements in the understanding of the molecular mechanisms underlying melanoma biology and in defining new curative strategies, the therapeutic needs for ... [more ▼]

Melanoma is the deadliest skin cancer. Despite improvements in the understanding of the molecular mechanisms underlying melanoma biology and in defining new curative strategies, the therapeutic needs for this disease have not yet been fulfilled. Herein, we provide evidence that the Activating Molecule in Beclin-1-Regulated Autophagy (Ambra1) contributes to melanoma development. Indeed, we show that Ambra1 deficiency confers accelerated tumor growth and decreased overall survival in Braf/Pten-mutated mouse models of melanoma. Also, we demonstrate that Ambra1 deletion promotes melanoma aggressiveness and metastasis by increasing cell motility/invasion and activating an EMT-like process. Moreover, we show that Ambra1 deficiency in melanoma impacts extracellular matrix remodeling and induces hyperactivation of the focal adhesion kinase 1 (FAK1) signaling, whose inhibition is able to reduce cell invasion and melanoma growth. Overall, our findings identify a function for AMBRA1 as tumor suppressor in melanoma, proposing FAK1 inhibition as a therapeutic strategy for AMBRA1 low-expressing melanoma. [less ▲]

Testing informed SIR based epidemiological model for COVID-19 in Luxembourg

E-print/Working paper (2020)

The interpretation of the number of COVID-19 cases and deaths in a country or region is strongly dependent on the number of performed tests. We developed a novel SIR based epidemiological model (SIVRT ... [more ▼]

The interpretation of the number of COVID-19 cases and deaths in a country or region is strongly dependent on the number of performed tests. We developed a novel SIR based epidemiological model (SIVRT) which allows the country-specific integration of testing information and other available data. The model thereby enables a dynamic inspection of the pandemic and allows estimating key figures, like the number of overall detected and undetected COVID-19 cases and the infection fatality rate. As proof of concept, the novel SIVRT model was used to simulate the first phase of the pandemic in Luxembourg. An overall number of infections of 13.000 and an infection fatality rate of 1,3 was estimated, which is in concordance with data from population-wide testing. Furthermore based on the data as of end of May 2020 and assuming a partial deconfinement, an increase of cases is predicted from mid of July 2020 on. This is consistent with the current observed rise and shows the predictive potential of the novel SIVRT model. [less ▲]